Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Alvimopan. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | OPRM1 known ✓ | P35372 | 14/20 | 1.00 |
| ▸ | OPRD1 | P41143 | 14/20 | 1.00 |
| ▸ | OPRK1 | P41145 | 11/20 | 1.00 |
| ▸ | KCNE1 | P15382 | 1/20 | 1.00 |
| ▸ | KCNQ1 | P51787 | 1/20 | 1.00 |
| ▸ | CACNA1C | Q13936 | 1/20 | 1.00 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Alvimopan SCHEMBL19367975 | 1.00 | OPRM1 (1.00) | OPRM1OPRD1OPRK1KCNE1KCNQ1 | |
| Alvimopan SCHEMBL12188165 | 1.00 | OPRM1 (1.00) | OPRM1OPRD1OPRK1KCNE1KCNQ1 | |
| Alvimopan SCHEMBL16449956 | 1.00 | OPRM1 (1.00) | OPRM1OPRD1OPRK1KCNE1KCNQ1 | |
| Alvimopan SCHEMBL13913401 | 1.00 | OPRM1 (1.00) | OPRM1OPRD1OPRK1KCNE1KCNQ1 | |
| Alvimopan SCHEMBL19367933 | 1.00 | OPRM1 (1.00) | OPRM1OPRD1OPRK1KCNE1KCNQ1 | |
| Alvimopan SCHEMBL14995531 | 1.00 | OPRM1 (1.00) | OPRM1OPRD1OPRK1KCNE1KCNQ1 | |
| Alvimopan SCHEMBL25348849 | 1.00 | OPRM1 (1.00) | OPRM1OPRD1OPRK1KCNE1KCNQ1 | |
| Alvimopan SCHEMBL5953724 | 1.00 | OPRM1 (1.00) | OPRM1OPRD1OPRK1KCNE1KCNQ1 | |
| Alvimopan SCHEMBL1477341 | 0.99 | OPRM1 (0.98) | OPRM1OPRD1OPRK1KCNE1KCNQ1 | |
| Alvimopan SCHEMBL8786261 | 0.99 | OPRM1 (0.98) | OPRM1OPRD1OPRK1KCNE1KCNQ1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Appears in 2127 patents — a generic fragment claimed broadly, so it's down-weighted as IP noise. Top by claim status then date:
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12617816-B2 | Composition and method for in vivo assay of opioid receptors | THE TRUSTEES OF DARTMOUTH COLLEGE (US) | 2026-05-05 | — | — | US | claimed |
| US-12569478-B2 | Sequestration compounds for treatment of substance use disorder and uses thereof | CLEAR SCIENTIFIC, INC. (US) | 2026-03-10 | — | — | US | claimed |
| EP-4633677-A1 | VIROPORINS BLOCKERS/INHIBITORS AS ANTI-INFLUENZA AGENTS | Yissum Research Development Company of the Hebrew University of Jerusalem Ltd. (IL) | 2025-10-22 | — | — | EP | claimed |
| US-20250246289-A1 | DYNAMICALLY TARGETING SUBSTANCE USE DISORDERS AND CONDITIONS VIA PERSONALIZED DIGITAL THERAPEUTICS | Click Therapeutics, Inc. (US) | 2025-07-31 | — | — | US | claimed |
| WO-2025137697-A1 | METHODS, SYSTEMS, AND COMPOSITIONS RELATED TO USE OF MU OPIOID RECEPTOR (MOR) ANTAGONISTS | GLYCYX MOR INC. (US) | 2025-06-26 | — | — | WO | claimed |
| US-20250186423-A1 | METHODS OF TREATING CANCER AND OTHER CONDITIONS WITH A MU OPIOID RECEPTOR ANTAGONIST | GLYCYX MOR INC (US) | 2025-06-12 | — | — | US | claimed |
| WO-2025111482-A1 | COMPLEXING AGENT SALT FORMULATIONS OF PHARMACEUTICAL COMPOUNDS AT LOW STOICHIOMETRIC RATIOS | BEXSON BIOMEDICAL, INC. (US) | 2025-05-30 | — | — | WO | claimed |
| CN-119584986-A | Methods of treating cancer and other disorders using Mu opioid receptor antagonists | 格莱赛克斯摩尔公司 | 2025-03-07 | — | — | CN | claimed |
| US-20240390364-A1 | Novel Pyridine Compositions and their use in methods for preventing or treating diseases, disorders and conditions | REID CHRISTOPHER BRIAN (US) | 2024-11-28 | — | — | US | claimed |
| US-20240390490-A1 | PHARMACEUTICAL COMPOSITIONS FOR THE TREATMENT OF CANCERS | RUTGERS, THE STATE UNIVERSITY OF NEW JERSEY (US) | 2024-11-28 | — | — | US | claimed |
| WO-2005107806-A1 | COMPOSITIONS FOR AFFECTING WEIGHT LOSS | OREXIGEN THERAPEUTICS, INC. (US) | 2005-11-17 | — | — | WO | claimed |
| WO-2005074931-A1 | PHARMACEUTICAL COMBINATIONS COMPRISING (S) -PANTOPRAZOLE | ALTANA PHARMA AG (DE) | 2005-08-18 | — | — | WO | claimed |
| CN-1655784-A | Use of compounds that are potent selective opioid receptor modulators | MERCK PATENT GMBH (DE) | 2005-08-17 | — | — | CN | claimed |
| US-20050176746-A1 | Use of compounds that are effective as selective opiate receptor modulators | TIOGA PHARMACEUTICALS, INC. | 2005-08-11 | — | — | US | claimed |
| WO-2005046687-A1 | USE OF SELECTIVE OPIATE RECEPTOR MODULATORS IN THE TREATMENT OF NEUROPATHY | TIOGA PHARMACEUTICALS, INC. (US) | 2005-05-26 | — | — | WO | claimed |
| EP-1505974-A2 | USE OF COMPOUNDS THAT ARE EFFECTIVE AS SELECTIVE OPIATE RECEPTOR MODULATORS | MERCK PATENT GmbH (DE) | 2005-02-16 | — | — | EP | claimed |
| US-20040254208-A1 | Using mixture of opioid receptor antagonist and melanocortin antagonist; suppression appetites | WILMINGTON SAVINGS FUND SOCIETY, FSB | 2004-12-16 | — | — | US | claimed |
| WO-2004105795-A1 | PHARMACEUTICAL COMBINATIONS OF A PROTON PUMP INHIBITOR AND A COMPOUND WHICH MODIFIES GASTROINTESTINAL MOTILITY | ALTANA PHARMA AG (DE) | 2004-12-09 | — | — | WO | claimed |
| WO-2004096201-A1 | COMPOSITIONS FOR AFFECTING WEIGHT LOSS | OREXIGEN THERAPEUTICS, INC. (US) | 2004-11-11 | — | — | WO | claimed |
| WO-2003097051-A2 | USE OF COMPOUNDS THAT ARE EFFECTIVE AS SELECTIVE OPIATE RECEPTOR MODULATORS | MERCK PATENT GMBH (DE) | 2003-11-27 | — | — | WO | claimed |